about
Benzo(a)pyrene-caused increased G(1)-S transition requires the activation of c-Jun through p53-dependent PI-3K/Akt/ERK pathway in human embryo lung fibroblastsA WD-FYVE protein binds to the kinases Akt and PKCzeta/lambdaNaturally secreted amyloid-beta increases mammalian target of rapamycin (mTOR) activity via a PRAS40-mediated mechanismMammalian target of rapamycin: a central node of complex signaling cascadesMolecular biology of lung cancer: clinical implicationsmTOR inhibitors in advanced renal cell carcinomaTargeting mTOR for the treatment of AML. New agents and new directionsThe de-ubiquitinase UCH-L1 is an oncogene that drives the development of lymphoma in vivo by deregulating PHLPP1 and Akt signalingE3 ligase Nedd4 promotes axon branching by downregulating PTENSwitching Akt: from survival signaling to deadly responseMolecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments.Negative Regulation of AKT Activation by BRCA1Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagyMel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cellsAkt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapyRapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signalingHypoxia-inducible factor-1alpha polymorphisms and TSC1/2 mutations are complementary in head and neck cancersFXYD5: Na(+)/K(+)-ATPase Regulator in Health and DiseaseSystematic Review of Pharmacological Properties of the Oligodendrocyte LineageCharacterizing autism spectrum disorders by key biochemical pathways.Potential Effects of Pomegranate Polyphenols in Cancer Prevention and TherapySomatic mosaicism in the human genomeRole of leptin and its receptors in the pathogenesis of thyroid cancerPulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoidsProtein kinase inhibitors against malignant lymphomaRegulation of brain tumor dispersal by NKCC1 through a novel role in focal adhesion regulationRegulation of Hepatitis B Virus Replication by the Phosphatidylinositol 3-Kinase-Akt Signal Transduction PathwayThe Role of ATRX in the Alternative Lengthening of Telomeres (ALT) PhenotypeThe Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent CellsmTOR generates an auto-amplification loop by triggering the βTrCP- and CK1α-dependent degradation of DEPTORmTOR signaling in tumorigenesisHepatocyte nuclear factor 1A (HNF1A) as a possible tumor suppressor in pancreatic cancerFoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasisS9, a novel anticancer agent, exerts its anti-proliferative activity by interfering with both PI3K-Akt-mTOR signaling and microtubule cytoskeletonProtein tyrosine kinase 6 negatively regulates growth and promotes enterocyte differentiation in the small intestinePten regulates neuronal arborization and social interaction in mice.Sensitizing the therapeutic efficacy of taxol with shikonin in human breast cancer cellsTargeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092Targeting the phosphoinositide 3-kinase pathway in cancerMammalian target of rapamycin (mTOR) regulates cellular proliferation and tumor growth in urothelial carcinoma.
P2860
Q23921356-E16F7711-F41B-41B5-ADA9-B138184DE211Q24294538-32D5CA73-0EFB-49F6-9BC5-16EE3241A58DQ24595310-817572C2-0FE3-43B1-BA39-59C40363FED4Q24601702-C12C1816-192D-4926-9930-6A32C98DA158Q24610335-647EF0F7-3F61-4C98-BAEE-9FEFA163A913Q24612127-6635D6D3-FF11-49D0-A648-3D362784FECFQ24617223-BED546AC-3E92-4339-94C7-749795FE05A7Q24629152-C33E5583-674B-4C9A-B63C-DDF4C91AC85BQ24630190-7A7A3D15-A63F-4A05-ACFF-34B4F59AB453Q24632379-E5F7300C-86B8-4323-8D46-618EB58D83F6Q24633947-306E9F43-13C3-450C-9AAF-90C3D8292B5CQ24644153-48B2EE13-2174-4937-89EE-2C5D60128267Q24645466-4AC3E76F-4F17-4341-B98C-9E772AB1CE31Q24654211-62E91C45-D233-4715-B9E0-EC8D7E959B99Q24655510-4F12DB1D-8D92-45AB-9285-1B7A8F0B3CD4Q24673299-D92357F0-D8D2-4903-8E61-DEAADDBE638BQ25255621-7734B703-7B60-4058-AE92-86713566193EQ26749337-A92B7E0D-CF2F-4BEE-BD42-AE6DFDDC6A37Q26768210-49CE3416-CC83-4466-9700-495B01FC4091Q26781645-CDB59426-FD3D-43BD-8B21-487A716F38CDQ26800877-910FB25C-A253-4EF5-975B-ADB07362C938Q26823199-C899EDDD-4775-490B-8519-EC97D767A0A6Q26823755-80F92156-FEF0-49D1-9714-AA25EF297197Q26996521-6845D6E0-F62B-4C6F-9C58-F9382EBDDCF2Q27024212-87DB6B02-020D-4F43-A4DC-02F5C5D81DB0Q27319526-73FCE080-A46F-4E43-AAF1-0F8C7A29426FQ27481454-5787B38B-6D6A-495C-AAFD-B120261ADD1BQ28071562-5A41E6AE-4FC3-4FFB-9AFC-CE3FBA9BE914Q28074203-59B77216-8632-4A24-8E82-5D41DE6F4FF0Q28251047-508F130E-6B29-4BAE-82C9-DB153C346450Q28252695-E8058762-AE80-4AAF-B075-F1A036E1FDAAQ28259270-7EC2CA67-7935-4306-B110-3D7BE579A8DBQ28285131-5893C8EC-6C42-43C9-8615-0EA8A669E35CQ28475032-2207A50D-8B98-4C83-8403-E61CD7AE9FC4Q28509681-A30DE14D-AB83-4232-A097-5D4F21D2295EQ28512488-1A2ED72B-CB3C-454F-B005-6B943BD7F06AQ28542057-FA693D88-C513-4B3F-83C5-2AD0EFE725C9Q28550300-C4EE6352-D8EF-470A-8537-6FEDE30C5342Q29615809-7FB5B69A-99ED-498C-A042-267F55CD2C1FQ30432032-C4193632-3C14-40D3-B137-3F88284F8163
P2860
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
The Akt-mTOR tango and its relevance to cancer.
@ast
The Akt-mTOR tango and its relevance to cancer.
@en
type
label
The Akt-mTOR tango and its relevance to cancer.
@ast
The Akt-mTOR tango and its relevance to cancer.
@en
prefLabel
The Akt-mTOR tango and its relevance to cancer.
@ast
The Akt-mTOR tango and its relevance to cancer.
@en
P1433
P1476
The Akt-mTOR tango and its relevance to cancer.
@en
P2093
Nissim Hay
P304
P356
10.1016/J.CCR.2005.08.008
P577
2005-09-01T00:00:00Z